Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
15 Preposterous Cosplay Ensembles That Will Blow You Away - 2Smooth countdown continues for Artemis II moon mission
- 3Most loved Caf\u00e9 Chain: Where Do You Get Your Caffeine Fix
- 4'Stranger Things' series finale trailer shows Hawkins gang gearing up for last battle with Vecna
- 5The race to mine the moon is on – and it urgently needs some clear international rules
- Dick Van Dyke shares his secrets to longevity as he turns 100
- Discovering a true sense of harmony: Contemplation and Care Practices
- Protester climbs on to balcony of Iranian embassy in London
- Exposure to neighborhood violence leads some Denver teens to use tobacco and alcohol earlier, new study shows
- Home Wellness Basics: Building Your Home Exercise center
- 'We need everyone,' wounded reservist urges Knesset panel to advance haredi draft law
- Artemis II astronauts say they're "ready to go" for moon launch
- From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected
- Geminid meteors streak under green sky | Space photo of the day for Dec. 19, 2025
